Zacks Research Has Bullish Outlook for Cingulate Q3 Earnings

Key Points

• Zacks Research raised its Q3 2026 EPS forecast for Cingulate to a loss of $0.55 per share from a prior estimate of $0.57, while projecting losses of $2.38, $2.30 and $1.02 per share for fiscal years 2026–2028.
• Cingulate’s latest quarterly loss of $0.45 per share beat analyst expectations of a $0.63 loss by $0.18. The stock had opened at $5.33, with a market capitalization of approximately $77.5 million.
• Analyst sentiment remains mixed but leans positive: three analysts rate the stock Buy and one rates it Sell, producing a “Moderate Buy” consensus and an average price target of $27.33. Institutional investors own 41.31% of the company.

Cingulate Inc. (NASDAQ:CING - Free Report) - Stock analysts at Zacks Research raised their Q3 2026 earnings per share (EPS) estimates for Cingulate in a research report issued to clients and investors on Wednesday, August 19th. Zacks Research analyst J. Vandermosten now expects that the company will post earnings per share of ($0.55) for the quarter, up from their previous forecast of ($0.57). The consensus estimate for Cingulate's current full-year earnings is ($2.40) per share. Zacks Research also issued estimates for Cingulate's FY2026 earnings at ($2.38) EPS, FY2027 earnings at ($2.30) EPS and FY2028 earnings at ($1.02) EPS.

Cingulate (NASDAQ:CING - Get Free Report) last issued its earnings results on Thursday, August 13th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.63) by $0.18.

A number of other analysts have also weighed in on CING. Weiss Ratings lowered shares of Cingulate from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday. Roth Capital restated a "buy" rating and set a $10.00 target price on shares of Cingulate in a research report on Tuesday, May 19th. Ascendiant Capital Markets lowered their price target on shares of Cingulate from $55.00 to $52.00 and set a "buy" rating on the stock in a report on Monday, June 8th. Wall Street Zen raised Cingulate from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th. Finally, HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Cingulate in a research note on Tuesday, May 26th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Cingulate presently has a consensus rating of "Moderate Buy" and an average price target of $27.33.

Cingulate Trading Up 1.1%

Shares of NASDAQ CING opened at $5.33 on Friday. Cingulate has a 12 month low of $3.16 and a 12 month high of $11.89. The company has a 50 day simple moving average of $4.96 and a two-hundred day simple moving average of $5.58. The stock has a market cap of $77.50 million, a price-to-earnings ratio of -1.48 and a beta of -0.90.

Institutional Investors Weigh In On Cingulate

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE increased its holdings in shares of Cingulate by 283.1% during the 2nd quarter. Bank of America Corp DE now owns 7,501 shares of the company's stock valued at $31,000 after purchasing an additional 5,543 shares in the last quarter. Soltis Investment Advisors LLC purchased a new stake in Cingulate during the fourth quarter worth $43,000. XTX Topco Ltd purchased a new stake in Cingulate during the second quarter worth $45,000. Quadrature Capital Ltd purchased a new stake in Cingulate during the fourth quarter worth $66,000. Finally, Chicago Partners Investment Group LLC acquired a new stake in Cingulate during the first quarter valued at $116,000. Institutional investors and hedge funds own 41.31% of the company's stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source